What MEGGLE does

MEGGLE is a German family-owned pharmaceutical excipient manufacturer headquartered in Bruckmühl, Bavaria, with a secondary production facility in the USA. Founded in 1887, the company has produced lactose and co-processed excipients for over 75 years and supplies pharmaceutical manufacturers across 110 countries. Its product portfolio is organized into five categories — sieved lactose, milled lactose, direct compression lactose (agglomerated, spray-dried, anhydrous), co-processed excipients (Cellactose 80, MicroceLac 100, StarLac, RetaLac, CombiLac, MicroceLac Plus), and dry powder inhalation (DPI) lactose grades — supported by specialized offerings such as Lactose Monohydrate Low Endotoxin and Compaction Blend M.

Name

MEGGLE

Legal name

MEGGLE GmbH & Co. KG

Website

https://meggle-pharma.com

Company type

Private

Founded year

1887

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Wasserburg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Excipients Sales: B2B sales of pharmaceutical-grade lactose and co-processed excipients to pharmaceutical manufacturers for tablet, capsule, powder formulation, and inhalation applications

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

MEGGLE manufactures and sells pharmaceutical-grade lactose and co-processed excipients for tablet, capsule, powder formulation, and dry powder inhalation (DPI) applications. The company operates two state-of-the-art production facilities in Germany and the USA and supplies its excipients to pharmaceutical manufacturers across 110 countries, supported by a global network of application laboratories (ExciLabs) and technical advisors.

Product overview

MEGGLE Excipients is a pharmaceutical excipient company with over 70 years of experience producing high-quality lactose and co-processed excipients for tablets, capsules, powder formulations, and dry powder inhalation (DPI) applications. The product portfolio is organized into five main lactose categories: (1) Sieved Lactose (PrismaLac 40, CapsuLac 60, SacheLac 80, SpheroLac 100); (2) Milled Lactose (GranuLac 70/70 US, 80, 140/140 US, 200/200 US/200 Low Nitrite, 230/230 Low Nitrite, SorboLac 400); (3) Direct Compression (DC) lactose including agglomerated (Tablettose 70, 80, 100/100 Low Nitrite), spray-dried (FlowLac 90, 100/100 Low Nitrite), anhydrous (DuraLac H), and co-processed excipients (Cellactose 80, MicroceLac 100, MicroceLac Plus, CombiLac, StarLac, RetaLac); (4) DPI lactose grades spanning sieved (InhaLac 70, 120, 160, 230, 240, 251), milled (InhaLac 140, 145, 150, 180), and fine milled variants (InhaLac 300, 400, 500); and (5) Special Applications including Lactose Monohydrate Low Endotoxin and Compaction Blend M. Complementing the product portfolio are digital tools including the Product Configurator, Nitrosamine Risk Assessment Calculator, DPI Blend Prediction Tool, and DPI Selection Guide, supported by ExciLabs application laboratories and DPI customization services. MEGGLE operates two production facilities in Germany and the USA and supplies to over 110 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Sieved Lactose (PrismaLac 40, CapsuLac 60, SacheLac 80, SpheroLac 100) Sieved lactose excipients produced through sieving processes to achieve precise particle size distribution, used by pharmaceutical manufacturers in tablet and capsule formulations.
• Milled Lactose (GranuLac 70, 80, 140, 200, 230, SorboLac 400) Milled lactose excipients offering varied particle size distributions for tablet and capsule formulations, including US pharmacopeia-compliant variants.
• Direct Compression Lactose (Tablettose, FlowLac, DuraLac H) Lactose excipients including agglomerated (Tablettose 70, 80, 100), spray-dried (FlowLac 90, 100), and anhydrous (DuraLac H) grades engineered for direct compression tablet manufacturing.
• Co-processed Excipients (Cellactose 80, MicroceLac 100, MicroceLac Plus, CombiLac, StarLac, RetaLac) Advanced lactose-based co-processed excipients combining lactose with cellulose, microcrystalline cellulose, starch or other excipients to deliver enhanced functional properties for tablet and capsule formulations.
• Dry Powder Inhalation Lactose (InhaLac 70, 120, 140, 145, 150, 160, 180, 230, 240, 251, 300, 400, 500) Inhalation-grade lactose excipients in sieved, milled, and fine milled grades with controlled particle sizes for dry powder inhaler (DPI) formulations.
• Special Application Lactose (Lactose Monohydrate Low Endotoxin, Compaction Blend M) Specialized lactose excipients including low endotoxin lactose monohydrate and Compaction Blend M for sensitive pharmaceutical and specialized compaction applications.
• MEGGLE Low Nitrite Lactose Grades New premium lactose grades with controlled low nitrite levels developed using ion chromatography to minimize nitrosamine formation risk in pharmaceutical formulations.
• ExciLabs Application Laboratories MEGGLE's global network of application laboratories where expert teams provide formulation support and turn formulation challenges into excipient solutions for pharmaceutical manufacturers.
• DPI Customized Lactose Customization service that tailors inhalation-grade lactose to meet the exact particle size and blending ratio requirements of dry powder inhaler (DPI) development projects.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Colorcon: US specialty company providing pharmaceutical excipients, coatings, and formulation aids. Colorcon competes with MEGGLE in direct compression excipients, controlled-release coatings, and DPI formulation support, addressing overlapping pharmaceutical manufacturer customers.
• Roquette: French global leader in starches, polyols, and pharmaceutical excipients. Roquette competes directly with MEGGLE in pharmaceutical lactose, cyclodextrins, and co-processed excipients for tablet and capsule formulations, with comparable global manufacturing footprint and customer base.
• Avantor: US-based manufacturer and distributor of pharmaceutical ingredients, excipients, and high-purity materials. Avantor's pharmaceutical excipient portfolio overlaps materially with MEGGLE's offerings, serving similar pharmaceutical customers across formulation and DPI applications.
• DFE Pharma: Dutch pharmaceutical excipient manufacturer specializing in lactose, co-processed excipients, and inhalation-grade products. DFE Pharma is the most direct competitor to MEGGLE, serving the same pharmaceutical customers with overlapping product portfolios across oral solid dose and DPI applications.
• SPI Pharma: Specialty pharmaceutical excipient manufacturer with portfolio including antacid actives, co-processed excipients, and direct compression systems. SPI Pharma competes with MEGGLE in co-processed excipients for oral solid dose formulations, serving similar pharmaceutical customers.

Broad incumbents

• BASF: German chemical giant with broad pharmaceutical excipient portfolio serving pharma manufacturers globally. While not specialized in lactose, BASF's pharma ingredients business overlaps with MEGGLE's excipient offerings as part of a much larger diversified portfolio.
• Merck KGaA (Life Science): German life science company with significant pharmaceutical ingredients and excipients business through its Life Science sector. Operates broadly across pharma materials, bioprocessing, and lab products with partial overlap to MEGGLE's excipient portfolio.
• IFF (DuPont Nutrition & Biosciences): Large ingredient company with pharmaceutical excipient offerings as part of broader food and beverage portfolio. IFF's pharma excipient business overlaps with MEGGLE in select biopolymers and formulation aids but lacks MEGGLE's focus on pharmaceutical lactose.
• Kerry Group: Irish multinational with pharmaceutical and food ingredient divisions. Kerry's pharmaceutical excipient offerings overlap with MEGGLE in select categories as part of a broader taste, nutrition, and ingredient portfolio rather than as a focused pharmaceutical excipient specialist.

Others

• IMCD: Dutch specialty chemicals and ingredients distributor representing multiple pharmaceutical excipient manufacturers. IMCD serves as a complementary distribution channel and ecosystem participant for pharma excipients rather than a direct manufacturing competitor to MEGGLE.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/meggle.srbija

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEGGLE